Bergamot

What is Bergamot?

Bergamot is one fruit sold as two entirely different products. Citrus bergamia Risso et Poiteau (Rutaceae) is a sour, thick-rinded citrus grown almost nowhere else on earth: roughly 90 percent of world essential oil production comes from fewer than 1,400 hectares along the Ionian coast of Reggio Calabria, Italy, yielding 70,000 to 100,000 kg of oil a year. The peel gives cold-pressed bergamot essential oil, which flavors Earl Grey tea and anchors the top note of countless fragrances. The juice, which for most of the industry's history was poured away as waste, gives the polyphenol extract sold in capsules as Bergamot Polyphenolic Fraction or simply "citrus bergamot," marketed for LDL cholesterol.

The two share a name and almost nothing else. The oil is a terpene mixture with a furocoumarin problem. The juice extract is a flavanone glycoside mixture with genuinely interesting statin-like chemistry and a thin, mostly Italian evidence base. Confusing them is the most common error a buyer makes, and some sellers do not work hard to prevent it.

Common Names

• Bergamot, bergamot orange, bergamotto

• Citrus bergamia Risso et Poit.; also written Citrus x bergamia

• Citrus aurantium L. subsp. bergamia Wright et Arn., the name the US FDA uses in its GRAS flavoring list at 21 CFR 182.20

• Bergamot Polyphenolic Fraction (BPF), citrus bergamot extract, bergamot flavonoid extract

• Bergamot FCF, bergapten-free bergamot oil, BF bergamot oil, all names for the furocoumarin-reduced essential oil

• Name collision worth flagging: "wild bergamot" and "bee balm" are Monarda fistulosa and Monarda didyma, North American mints in the Lamiaceae, named for a superficial aroma resemblance and unrelated to Citrus bergamia. A product labeled "wild bergamot" contains no bergamot flavanones and no bergapten.

Primary Active Compounds

• In the cold-pressed peel oil: limonene 25 to 55 percent, linalyl acetate 15 to 40 percent, linalool 2 to 20 percent, with more than 100 volatile compounds detected overall

• In the oil's non-volatile fraction, which is 4 to 7 percent of the oil by weight: bergapten (5-methoxypsoralen) 0.11 to 0.32 percent, bergamottin (5-geranyloxypsoralen) 1.02 to 2.75 percent, citropten 0.14 to 0.35 percent, 5-geranyloxy-7-methoxycoumarin 0.08 to 0.22 percent

• In the juice: neoeriocitrin, naringin and neohesperidin, measured by Gardana and colleagues in Molecules in 2008 at 73.3, 167.5 and 123.9 mg/L respectively

• Brutieridin and melitidin, the two 3-hydroxy-3-methylglutaryl flavanone glycosides isolated by Di Donna and colleagues in the Journal of Natural Products in 2009, which carry a side chain resembling the statin pharmacophore

• Also in the juice: bergapten at 9.0 mg/L and bergamottin at 18.2 mg/L, which matters for drug interactions and is almost never disclosed

Key Note

The plant is an interspecific hybrid, most often proposed as bitter orange (Citrus x aurantium) crossed with lemon (Citrus x limon). The essential oil carries a European Protected Designation of Origin, "Bergamotto di Reggio Calabria, Olio essenziale," registered on 15 March 2001, which specifies a yield of 350 to 750 g of oil per 100 kg of fruit. That PDO governs the oil. It does not govern the capsules.

Everything below separates the two product streams, because the safety issues, the regulatory treatment and the evidence quality differ for each.

Primary Functions & Benefits

Bergamot has three claimed uses resting on very different amounts of evidence.

Lipid lowering, from the juice-derived polyphenol extract. The only bergamot application with repeated human trials, pooled most recently by Sadeghi-Dehsahraei in Phytotherapy Research in 2022 (14 trials) and by Osadnik in Pharmacological Research the same year (131 trials, 13,062 participants), the latter ranking bergamot first among nutraceuticals for LDL-C reduction. Sections 11 and 20 give the numbers and the reasons to discount them.

Glycemic and metabolic endpoints. Mollace's 2011 cohort of 237 patients included people with hyperglycaemia and reported falls in fasting glucose alongside the lipid changes. A 2026 meta-analysis of 11 randomized trials in Obesity Reviews found reductions in body weight (SMD -0.64), BMI (SMD -0.85) and waist circumference (SMD -0.41), with heterogeneity of 90 percent for the first two.

Aromatherapy for mood, anxiety and sleep, from the peel oil. Small randomized trials, usually combining bergamot with lavender. Salehi-Pourmehr randomized 132 postmenopausal women aged 50 to 60 in Complementary Therapies in Medicine in 2025, finding an adjusted mean difference of -5.7 on menopausal symptoms and -1.9 on anxiety. In a 2025 three-arm trial of 90 women with premenstrual syndrome, grapefruit oil outperformed bergamot on the primary scale.

Forms & Standardization

This is where the money is spent and where the buyer has the least information.

Cold-pressed (expressed) peel oil. Produced mechanically, most often by pelatrice, an abrasive rasping of the intact peel before juicing, or by sfumatrice, roller pressing of the peel after the juice is taken. Cold pressing carries over both the volatiles and the non-volatile 4 to 7 percent residue that contains the furocoumarins. This is the oil the IFRA 0.40 percent limit applies to, and the oil that causes the burns.

Bergapten-free or FCF oil. "FCF" stands for furanocoumarin-free, and the label describes a process, not a guarantee of zero. Alkaline treatment with sodium hydroxide hydrolyses the lactone ring of the furocoumarins and brings bergapten down to a reported 0 to 91 ppm. Vacuum re-distillation through a fractionating column gives 0 to 41 ppm. A commercial IFRA statement for a bergapten-free oil specified bergapten at or below 0.0005 percent, which is 5 ppm. Even 91 ppm in the neat oil is 100 to 600 times lower than the cold-pressed material, which is why FCF oil is treated as non-phototoxic in practice. It also smells different, because neither method leaves the aroma profile untouched.

Steam-distilled bergamot oil. Furocoumarins are not volatile enough to carry over, so a properly distilled oil is effectively furocoumarin-free. It is rarer and is not what the PDO covers.

Bergamot juice. Sour, intensely bitter and historically discarded. Polyphenol extraction starts from the juice, the albedo or the pomace. Di Donna and colleagues published a 2011 route in Food Chemistry recovering brutieridin and melitidin from bergamot albedo, explicitly framed as recycling essential oil industry waste.

Standardized oral extracts, the trial materials. Two products carry nearly all the human data.

• BPF, the "bergamot polyphenolic fraction" used by Mollace's group at Catanzaro, dosed at 500, 1,000 and 1,500 mg per day of extract. Commercial versions are typically standardized to 38 percent polyphenols, so a 1,000 mg capsule delivers roughly 380 mg of actual flavanones.

• Bergavit, from Bionap S.r.l., standardized to deliver 150 mg of flavonoids per daily dose, with a declared composition of 16 percent neoeriocitrin, 47 percent neohesperidin and 37 percent naringin. This is the material in the Toth 2016 six-month study and the Spina 2024 randomized placebo-controlled trial.

What is actually on US shelves. Pulled from real label text in the NIH Dietary Supplement Label Database, the range is wide and the chemistry is often wrong.

• "Citrus Bergamot extract, 38% bergamot polyphenols," 500 mg (NutriONN)

• "Citrus bergamia Risso fruit extract, 150 mg, 30% Polyphenolic flavanones comprised of Neoeriocitrin, Naringin, Neohesperidin, Melitidine, and Bruteridine," 500 mg (Jarrow Formulas)

• "Bergamonte full spectrum Citrus bergamia Risso extract complex," 1,000 mg (Double Wood)

• "BPF 47%" (BergaMet North America)

• "25:1 extract, standardized to 50% polyphenilic flavonones, equivalent to 25,000 mg of bergamot orange fruit," 1,000 mg (BioSchwartz, spelling reproduced from the label)

• "Citrus Bergamont Fruit Extract, standardized to a minimum of 40% Polyphenolic Flavones, a 25:1 extract equivalent to 12,500 mg of fresh citrus bergamot fruit" (Zazzee, spelling reproduced from the label)

• Gummies at a 10:1 ratio "equivalent to 5,000 mg" (aSquared Nutrition)

Two of those say "flavones," a different chemical class from the flavanones bergamot actually contains, and one misspells the fruit. A "25:1 extract equivalent to 25,000 mg of fruit" is a marketing sentence, not a specification: it gives a drying ratio and nothing about which flavanones survived or in what proportion. The number that matters is milligrams of standardized flavanones per day, and only a minority of labels print it.

Food Sources

The honest position here is that bergamot is not a meaningful dietary item anywhere outside Calabria, and the two food routes deliver very different things.

• Earl Grey tea. Flavored with bergamot peel oil, so the flavanones in the capsules are absent entirely. Orth and colleagues measured transfer into the infusion in Food Additives and Contaminants Part A in 2014: 66 percent of linalool crosses into the cup, but only 1.9 percent of the linalyl acetate survives intact, with 17.0 percent appearing as hydrolysed linalool and 19.9 percent as a spectrum of rearrangement products. A cup of Earl Grey is not a bergamot supplement in any sense.

• Bergamot juice. At 73.3 mg/L neoeriocitrin, 167.5 mg/L naringin and 123.9 mg/L neohesperidin, one litre of juice carries roughly 365 mg of the three principal flavanones, which is in the same range as a single 1,000 mg BPF capsule standardized to 38 percent. The catch is that bergamot juice is savagely sour and bitter, is almost never sold as a beverage, and carries 9.0 mg/L of bergapten and 18.2 mg/L of bergamottin along with the flavanones.

• Bergamot marmalade, candied peel and Turkish delight. Sugar-dominated, made from peel, and not a source of the juice flavanones at any useful dose.

• Other citrus. Naringin is abundant in grapefruit and neohesperidin in bitter orange, but brutieridin and melitidin are not found at comparable levels in ordinary citrus. That is the one genuine reason bergamot is not interchangeable with a grapefruit.

Eating your way to a trial dose is not realistic. This is one of the few ingredients where the capsule is the only practical route, which should raise rather than lower the standard of evidence you demand from it.

Who Should Take Bergamot

• Adults with mild to moderate hypercholesterolaemia who are not candidates for statin therapy, or who decline it, and who understand they are buying a supplement with 30-day and 4-month trial data rather than outcome data.

• People who are statin-intolerant. Mollace's 237-patient cohort included a subgroup who had discontinued statins and were given 1,500 mg per day of BPF, and Gliozzi's 2013 trial was explicitly designed around dose-sparing.

• Adults already on a statin whose LDL remains above target, where the 2013 rosuvastatin trial provides at least a plausible add-on rationale, and where a prescriber is watching the numbers.

• Nobody should take bergamot as a substitute for statin therapy when statin therapy is indicated for established cardiovascular disease. The bergamot literature contains no cardiovascular outcome trial, no mortality data, and no trial longer than six months.

• For the essential oil there is no "should take." Inhaled use in a diffuser is low-risk. Skin application is the part that needs the rules in the next section.

Who Should AVOID or Use Caution

Contraindications

• Do not apply cold-pressed bergamot oil to skin that will be exposed to sun, a tanning bed or any UVA source within roughly 12 to 24 hours. Dubertret and colleagues showed in Journal of Photochemistry and Photobiology B in 1990 that human skin photosensitivity peaks about 2 hours after application, and the reported cases include exposures well beyond that window.

• Do not use bergamot oil on skin at all in anyone with a history of photosensitivity disorder, active PUVA therapy, or use of a photosensitizing drug such as doxycycline, amiodarone or a fluoroquinolone.

• Avoid oral bergamot extract in pregnancy and lactation. There is no safety data, and the extract carries furocoumarins.

• Do not ingest cold-pressed bergamot essential oil. It is GRAS as a flavoring at flavoring levels under 21 CFR 182.20, which is not permission to swallow it by the dropper.

Use Caution

• Anyone on a CYP3A4-dependent drug. See Section 17. Bergamottin is 1.02 to 2.75 percent of the peel oil and 18.2 mg/L of the juice.

• Children. Skin is thinner, dilution errors are proportionally larger, and there is no pediatric data on either product.

• Anyone with reflux. Heartburn was the reported adverse event in the 2017 schizophrenia adjunct study at 500 mg twice daily.

• Anyone whose LDL is being managed for secondary prevention. Substituting an unproven supplement for proven therapy is the realistic harm here, and it is larger than any direct toxicity.

Critical Safety Point

The bergapten hazard travels through air as well as by contact. In the second case reported by Kaddu, Kerl and Wolf in 2001, the patient had no direct skin contact with the oil. He was exposed to aerosolized, evaporated aromatherapy oil in a sauna, then used a tanning bed, and developed disseminated bullous lesions within 48 to 72 hours.

Recommended Dosages

Bergamot Polyphenolic Fraction (BPF), standardized extract

500 to 1,500 mg per day of extract, taken as one or two doses. At the common 38 percent standardization, 1,000 mg of extract is about 380 mg of flavanones. Mollace 2011 used 500 and 1,000 mg per day in 237 patients over 30 days, with 1,500 mg per day in the statin-discontinued subgroup. Gliozzi 2013 used 1,000 mg per day for 30 days, alone and alongside rosuvastatin 10 mg.

Bergavit-type extract, standardized to flavonoid content

150 mg of flavonoids per day, delivered in Toth 2016 over 6 months and in Spina 2024 as a single 375 mg capsule over 4 months. Note that 150 mg of flavonoids is well below the flavanone load in 1,000 mg of 38 percent BPF, and both produced LDL reductions. Nobody has run a head-to-head dose-ranging trial, so the dose-response curve for bergamot flavanones in humans is genuinely unknown.

Essential oil, topical

Maximum 0.4 percent of a leave-on product applied to skin that may see UV light, which is the IFRA figure and the Tisserand Institute's maximum dermal use level. In practical terms that is roughly 1 drop of oil in 30 mL of carrier, not the 2 percent (about 12 drops per 30 mL) that general aromatherapy guides recommend for adult body oils. Bergapten-free or steam-distilled oil is not subject to that ceiling.

Essential oil, inhaled

Diffuser use at the manufacturer's stated rate. The 2025 postmenopausal trial used 2 to 3 drops on the forearm inhaled three times daily for 8 weeks, which is a skin application and would exceed the phototoxic ceiling if the oil were cold-pressed and the forearm went outdoors.

Duration

Trials run 30 days to 6 months. There is no human safety data on continuous oral bergamot extract beyond 6 months, and no data at all on repeated multi-year use.

Timing & Administration

Take BPF-type extracts with food. The flavanone glycosides are poorly absorbed intact, though no bergamot-specific bioavailability trial has settled whether food helps.

Mollace's protocol and most commercial dosing split 1,000 mg into two 500 mg doses, morning and evening. Toth 2016 and Spina 2024 used a single daily capsule. Neither pattern has been shown superior.

Gliozzi 2013 gave BPF 1,000 mg with rosuvastatin 10 mg daily without specifying separation, and reported an additive effect on LDL-C and urinary mevalonate. With any other CYP3A4 substrate, separating doses does not solve the problem, because mechanism-based inactivation is not a timing issue. The enzyme has to be resynthesized.

For the oil, apply nothing photosensitizing before sun. If you want the aroma on skin in daylight, buy the FCF grade and say so at the point of purchase.

Timeline of Effects

Days 0 to 30. The shortest interval at which lipid changes have been reported. Both Mollace 2011 and Gliozzi 2013 measured at 30 days and found significant reductions in total cholesterol, LDL-C and triglycerides. Neither had an intermediate measurement, so nothing is known about whether the effect appears at day 7 or day 25.

Weeks 8 to 12. Spina 2024 assessed at months 2, 3 and 4 and saw the lipid separation from placebo established by the two-month mark. Eight weeks is the shortest defensible personal trial.

Months 4 to 6. Toth 2016 measured at 6 months and reported the largest effects seen anywhere, including a 25 percent reduction in carotid intima-media thickness. Treat that particular number with suspicion, for reasons given in Section 20.

When to conclude it is not working. If a fasting lipid panel at 12 weeks on 1,000 mg per day of a properly standardized extract shows no movement in LDL-C, it is not going to move at 24 weeks. Stop and use the money on something with outcome data.

For inhaled use. Anxiolytic and mood effects in the aromatherapy trials are measured within a single 30-minute session, and the 8-week trials measure durable change. There is no waiting period; if a single session does nothing for you, longer exposure is unlikely to help.

Benefits of Taking Bergamot

• LDL-C reduction. Toth 2016 reported LDL-C falling from 4.6 to 3.7 mmol/L over 6 months, a 20 percent drop, with p < 0.0001, in 80 subjects on 150 mg of flavonoids daily. Spina 2024, the better-controlled trial, reported a more modest 11.5 percent (p < 0.001) at 4 months in 60 completers. The 11.5 percent figure is the one to plan around.

• Triglyceride reduction. Reported across nearly every trial. Toth 2016 saw 1.8 to 1.5 mmol/L, a 17 percent fall, p = 0.0020. Mollace's 500 mg arm was reported at 30.5 percent.

• HDL-C increase. Small and consistent. Toth 2016 measured +8 percent (p = 0.0007); Spina 2024 measured +5.5 percent but at p = 0.067, which does not clear significance.

• Small dense LDL. Toth 2016 reported reductions of 38, 53 and 67 percent in LDL subfractions 3, 4 and 5. Small dense LDL is a plausible risk marker, not a validated treatment target.

• Oxidative markers. Spina 2024 measured oxidized LDL down 2.0 percent versus placebo and paraoxonase activity up 6.5 percent (p < 0.001). Gliozzi 2013 reported reductions in malondialdehyde, LOX-1 expression and phospho-PKB in peripheral polymorphonuclear cells.

• Statin dose-sparing. Gliozzi 2013 found BPF 1,000 mg plus rosuvastatin 10 mg outperformed rosuvastatin 10 mg alone on LDL-C and on urinary mevalonate, a direct readout of HMG-CoA reductase flux.

• Anxiety and menopausal symptoms, inhaled. Salehi-Pourmehr 2025 found an adjusted mean difference of -1.9 on anxiety and -1.7 on the Pittsburgh Sleep Quality Index in the aromatherapy arm of a 132-woman factorial trial.

• What is absent. No cardiovascular event data. No mortality data. No trial with a hard clinical endpoint of any kind.

Potential Negatives & Side Effects

• Phytophotodermatitis from the peel oil. Blistering, second-degree burns and long-lasting hyperpigmentation. Driscoll, Miller and Feldman published a 2021 case in Plastic Surgery Case Studies: a 25-year-old woman, Fitzpatrick type II, had lavender and bergamot oils applied to her upper chest during an acupuncture session and used a tanning bed about 2 hours later, producing mixed first and second degree burns over under 1 percent of body surface area, requiring non-excisional debridement and collagenase.

• Berloque dermatitis. Streaky, pendant-shaped hyperpigmentation on the neck and chest from bergamot-containing scent plus sun. Named by Rosenthal in 1925 after the German Berlock and French berloque, meaning trinket, and described by Freund as early as 1916. The pigment can persist for months after the inflammation settles.

• Heartburn and dyspepsia with the oral extract, the adverse event reported at 500 mg twice daily in the 2017 schizophrenia adjunct study.

• Contact sensitization to oxidized citrus oil components, chiefly limonene hydroperoxides formed as the oil ages. An old, warm, half-empty bottle is a different material from a fresh one.

• Drug interference through CYP3A4, covered in Section 17. This is the most likely route to real harm from the oral product.

• The opportunity cost. For someone with an LDL of 190 mg/dL and a family history, choosing a supplement with 4-month surrogate data over a statin with event data is the largest risk on this page.

Deficiency Symptoms

There is no such thing as bergamot deficiency. The human body has no requirement for neoeriocitrin, naringin, neohesperidin, brutieridin, melitidin or bergapten, no transport system dedicated to them, and no measurable status marker for any of them. No intake level has ever been defined by any authority because none is needed.

What bergamot addresses

Elevated LDL-C, elevated triglycerides and low HDL-C in people whose lipid abnormality has its own causes: diet, adiposity, insulin resistance, thyroid status, genetics. Bergamot is an intervention on a number, not the correction of a shortfall.

Bottom line

If a label implies your body is running low on bergamot flavanones, that is marketing language with no physiological content behind it.

Toxicity Symptoms

At high intake

Oral BPF has been given at 1,500 mg per day for 30 days without reported serious adverse events, and Spina 2024 found no significant change in hepatic or renal markers or fasting glucose over 4 months. That is the ceiling of what has actually been studied. Above it, nothing is known.

The peel oil is a different story. Finsterer published a case letter titled "Earl Grey tea intoxication" in The Lancet in 2002, volume 359, page 1484, describing a man drinking litres of Earl Grey daily who developed muscle cramps spreading from one foot to his calves and hands, distal paraesthesias in all limbs, and pressure behind the eyes with blurred vision. The author proposed bergapten acting as an axolemmal potassium channel blocker. After five months the patient reverted to plain black tea and the symptoms disappeared within a week. One case letter is one case letter, but the reversal on withdrawal is the informative part.

Signs to reduce or stop

• Any blistering, burning or unusual streaky darkening of skin after topical use plus sun. Stop the oil entirely and stay out of UV.

• New muscle cramping, tingling in the hands or feet, or visual disturbance in anyone consuming very large volumes of bergamot-flavored tea.

• Persistent heartburn or upper abdominal discomfort on the oral extract.

• Any unexpected intensification of an existing medication's effect, which is the CYP3A4 signal.

General note

The dangerous exposure here is dermal and photochemical, not systemic and dose-driven. A person can take a bergamot capsule for months with nothing worse than reflux and then get a chemical burn from four drops of the oil on their forearm before a beach walk. Those two facts sit under the same word on the shelf.

How Bergamot Works

The statin-like mechanism. Brutieridin and melitidin carry a 3-hydroxy-3-methylglutaryl moiety attached to a flavanone glycoside. That HMG group is the same structural feature that lets statins occupy the active site of HMG-CoA reductase, the rate-limiting enzyme of cholesterol synthesis. Di Donna's 2009 isolation paper in the Journal of Natural Products made exactly this argument, and Gliozzi's 2013 finding of reduced urinary mevalonate in BPF-treated patients is the strongest human evidence that the enzyme is inhibited in vivo, since mevalonate is the direct product of that reaction. The caution is that both compounds are minor constituents of the extract, their oral bioavailability has not been characterized in humans, and no study has shown plasma concentrations reaching the range needed to inhibit the enzyme meaningfully.

The flavanone mechanisms. Naringin, neohesperidin and neoeriocitrin are neohesperidoside glycosides, poorly absorbed intact and dependent on bacterial cleavage of the sugar in the large bowel before the aglycones can cross. Their proposed contributions are to intestinal cholesterol absorption, LDL receptor expression and oxidative modification of LDL, with most of that work done in cell culture and rodents rather than people.

The phototoxic mechanism. Bergapten is a linear furocoumarin. It intercalates between DNA base pairs, and UVA radiation at 320 to 400 nm drives a cycloaddition forming covalent monoadducts and interstrand crosslinks with pyrimidine bases. Cell death, inflammation and then a burst of melanogenesis follow, which is why the acute burn is succeeded by durable hyperpigmentation. This is the same chemistry PUVA therapy uses on purpose, under supervision, with a measured UVA dose.

The CYP3A4 mechanism. Bergamottin is a mechanism-based inactivator. Lin, Kenaan and Hollenberg showed in Drug Metabolism and Disposition in 2012 that CYP3A4 oxidizes bergamottin to a reactive intermediate, oxygenated 6',7'-dihydroxybergamottin, which covalently modifies glutamine 273 of the enzyme with a mass increase of 388 Da. A Q273V mutant resisted inactivation. The enzyme is destroyed, not merely occupied, so the effect lasts until new enzyme is made.

Synergistic Supplements

• Statins. The best-supported pairing, and the one with an actual trial behind it. Gliozzi 2013, n = 77, showed BPF 1,000 mg plus rosuvastatin 10 mg beating rosuvastatin 10 mg alone. Do this with a prescriber, not instead of one.

• Plant sterols and stanols. Reviews describe combination products of bergamot 500 mg with phytosterols achieving LDL-C reductions in the 7 to 8 percent range, which is roughly what sterols alone deliver, so the bergamot contribution in those formulas is unclear.

• Berberine and red yeast rice. Frequently formulated together for lipids. Red yeast rice contains monacolin K, which is chemically lovastatin, so stacking it with bergamot is stacking two HMG-CoA reductase inhibitors, one of them undeclared as a drug. That is not synergy so much as an unlabeled dose escalation.

• Artichoke leaf extract. A 2024 randomized placebo-controlled trial tested a dry artichoke plus bergamot combination in people with suboptimal cholesterol. Combination trials of this kind cannot attribute the effect to either ingredient.

• What is not synergy. Adding a second polyphenol because both are "antioxidants." Nothing in the bergamot literature supports that reasoning.

Interactions & What NOT to Take

The grapefruit-juice effect applies here. Bergamottin is one of the two furanocoumarins responsible for grapefruit's interaction profile, alongside 6',7'-dihydroxybergamottin. Fuhr and colleagues built a physiologically based pharmacokinetic model of both in Clinical Pharmacology and Therapeutics in 2023, describing grapefruit as a moderate to strong inactivator of CYP3A4, an enzyme involved in the metabolism of up to 50 percent of marketed drugs, with effects on victim drugs measurable up to 24 hours after a single exposure. Bergamot peel oil is 1.02 to 2.75 percent bergamottin. Bergamot juice carries 18.2 mg/L.

Named drugs to raise with a prescriber before starting oral bergamot

• Simvastatin and lovastatin, both heavily CYP3A4-dependent, where grapefruit-type inhibition raises exposure severalfold and rhabdomyolysis is the feared outcome. Rosuvastatin and pravastatin are far less CYP3A4-dependent, which is one reason the 2013 trial used rosuvastatin.

• Tacrolimus, ciclosporin and sirolimus

• Amiodarone, dronedarone, felodipine, nifedipine

• Apixaban and rivaroxaban

• Midazolam, triazolam

• Carbamazepine, ivabradine, ticagrelor

• Sildenafil and tadalafil

• Certain tyrosine kinase inhibitors and antiretrovirals

Photosensitizing drugs plus topical bergamot oil. Doxycycline, fluoroquinolones, amiodarone, thiazides, voriconazole and St John's wort all raise photosensitivity on their own. Adding a furocoumarin to skin on top of them is compounding a known hazard.

Antidiabetic drugs. Bergamot has reduced fasting glucose in several trials. If you are on metformin, a sulfonylurea or insulin, monitor rather than assume.

A frank gap. No published clinical pharmacokinetic study has measured whether a standard 1,000 mg dose of a commercial BPF capsule inhibits CYP3A4 in humans. The furocoumarins are present in the source material; whether they survive extraction and at what concentration is a manufacturer-specific question that almost no certificate of analysis answers.

Quality, Testing & Adulteration

The essential oil is heavily adulterated. Pierson, Fernandez and Antoniotti bought 11 bergamot essential oils online and tested them against ISO 3520, the international specification defining acceptable ranges for beta-pinene, gamma-terpinene, limonene, linalool, linalyl acetate, geranial and beta-bisabolene. Their results appeared in Scientific Reports in 2021. Exactly one of the 11 met all specifications. Two were grossly adulterated: one contained 60 percent triethyl citrate, confirmed by NMR, and another had been heavily cut with soybean oil. Both were the cheapest samples, at about 12.5 cents per mL.

Authenticity markers a real certificate of analysis should carry

• Enantiomeric purity of (3R)-(-)-linalyl acetate, which runs at 99.7 to 99.8 percent in genuine Calabrian oil and drops when synthetic racemic linalyl acetate is added

• The full ISO 3520 seven-compound profile with measured percentages, not a range copied from a textbook

• Absence of 5-geranyloxy-8-methoxypsoralen and 5-isopentenyloxy-7-methoxycoumarin, whose presence indicates lime oil has been blended in

• A measured bergapten figure in ppm. This is the single most useful number on a bergamot oil COA and it is almost never printed. If the seller cannot tell you the bergapten content, they cannot tell you whether the oil is safe to put on skin.

• For a bergapten-free oil, a stated method (alkali treatment or vacuum redistillation) and a measured residual, since the two methods give different residual ranges

For the oral extract

• Demand milligrams of standardized flavanones per serving, not a fruit-equivalent ratio.

• Look for a named, trial-linked material. Bergamonte and Bergavit are the two branded extracts with published human data attached, and a label naming one of them at least refers to a defined composition.

• Check whether the label lists brutieridin and melitidin. Some do, spelled variously as "Bruteridine" and "Melitidine." Listing them is not the same as quantifying them, and no label in the DSLD sample gives an amount.

• Ask for a furocoumarin assay. Given 9.0 mg/L bergapten in the source juice, this is a legitimate question and almost nobody asks it.

• There is no USP monograph for bergamot extract, no NSF certification specific to it, and no independent testing program that routinely publishes bergamot flavanone assays. Third-party verification here means whatever the individual brand chose to pay for.

The regulatory asymmetry, stated plainly. EU Regulation (EC) No 1223/2009 Annex II entry 358 prohibits furocoumarins in cosmetics "except for normal content in natural essences used," and sets a hard limit of below 1 mg/kg only in sun protection and bronzing products. The SCCP recommended on 13 December 2005 that total furocoumarins above 1 ppm in any finished cosmetic product would be a consumer safety concern; that broader recommendation was never written into the annex. In the US there is no furocoumarin limit in cosmetics at all. 21 CFR 740.10, on the books since March 1975, requires only the generic statement "Warning: The safety of this product has not been determined" for products whose safety is unsubstantiated. FDA's visible enforcement against essential oil sellers, including the warning letters issued to dōTERRA International and Young Living on 22 September 2014, concerned disease claims, not phototoxicity.

Special Considerations

Pregnancy and lactation. Avoid the oral extract. There is no human safety data, and bergapten is photomutagenic in test systems. Inhaled use in a diffuser is a lower-order concern but has no supporting data either.

Children. No pediatric dosing exists for either product. For the oil, the arithmetic works against children: a dilution error that puts 2 percent on a small forearm is a larger dose per unit body surface than the same error on an adult.

Skin type. Phototoxicity is not confined to fair skin, though the case reports skew toward Fitzpatrick I and II. Zaynoun and colleagues showed in Contact Dermatitis in 1977 that eye color, natural tanning tendency, age and sex had no effect on the phototoxic response, while vehicle, ethanol concentration, skin site, hydration and the interval before irradiation all did. Repeated photopatch testing at the same site increased sensitivity.

Sunscreen does not solve it. Dubertret's 1990 work found a UVA filter protected better than a UVB filter, but that sunscreens at 0.5 to 1 percent in a perfume could not suppress the phototoxicity of bergamot oil on human skin.

Supply fragility. Production is concentrated on under 1,400 hectares in one Italian province, and climate stress on that growing area has been raised in the literature as a threat to global supply. Constrained supply is historically when adulteration rates rise.

Tanning products. Bergamot oil was deliberately used as a tanning accelerator for decades, exploiting the melanogenic side of the same reaction that causes the burn. Moysan and colleagues measured 5-MOP at 1 to 4 ng/mL in suction blister fluid and about 1 ng/mL in plasma after repeated topical application of a commercial tanning preparation. The EU's 1 mg/kg limit in bronzing products exists because of that practice.

Research Status & Evidence Quality

Strong Evidence For

• Nothing, if "strong" means multiple large independent randomized controlled trials with hard endpoints. Bergamot has none.

Moderate Evidence For

• Reduction in LDL-C and triglycerides over 30 days to 6 months with standardized juice-derived extracts. Spina 2024 is the most methodologically sound single trial: randomized, double-blind, placebo-controlled, parallel-group, 64 randomized and 60 completed, 150 mg flavonoids daily for 4 months, LDL-C down 11.5 percent (p < 0.001) and total cholesterol down 8.8 percent (p < 0.01). It was funded by Bionap S.r.l., the ingredient manufacturer, with one author employed by the sponsor.

• Additive effect with rosuvastatin, from a single 77-patient open-label trial.

Emerging / Preliminary Evidence For

• Small dense LDL subfraction shifts, oxidized LDL and paraoxonase activity

• Fasting glucose and body composition. The 2026 Obesity Reviews meta-analysis of 11 RCTs found weight, BMI and waist circumference reductions with I-squared values of 90, 90 and 49 percent

• Inhaled bergamot for anxiety, mood and sleep, from small trials that mostly combine it with lavender and cannot separate the two

• Hepatic effects in non-alcoholic fatty liver disease, largely rodent work

• Anything involving brutieridin or melitidin specifically. Their statin-like structure is established chemistry. Their contribution to the clinical effect in humans is an inference, not a finding.

Research Limitations

• Concentration of authorship. A large share of the human trials trace to a small number of Italian groups, principally Mollace and colleagues at the University of Catanzaro in Calabria, the region whose economy depends on bergamot. That is not an accusation of misconduct. It is a structural reason to want independent replication, and independent replication is scarce.

• Design quality. Mollace 2011, the most-cited trial and the source of the headline percentages, is not described as randomized or blinded. Toth 2016 was open-label and prospective with no control group. Gliozzi 2013 was open-label. The properly randomized, double-blind, placebo-controlled trials, Spina 2024 among them, report noticeably smaller effects.

• Effect sizes that do not survive scrutiny. The 2022 meta-analysis in Phytotherapy Research pooled 14 trials and reported a weighted mean difference for LDL-C of -55.43 mg/dL (95% CI -67.26 to -43.60) and for triglycerides of -74.72 mg/dL. A 55 mg/dL LDL reduction is in the territory of moderate to high intensity statin therapy. No food-derived polyphenol does that, and the authors themselves wrote that the findings were "inconsistent" and that efficacy "needs to be further established through higher-quality studies." Osadnik's 131-trial network meta-analysis ranked bergamot first for LDL-C at -1.21 mmol/L, about -46.8 mg/dL, while flagging the "relatively small study group" behind it. When a supplement outranks statins in a pooled analysis, the pooled analysis is describing the quality of its inputs.

• The carotid IMT number. Toth 2016 reported carotid intima-media thickness falling from 1.2 to 0.9 mm in 6 months, a 25 percent reduction. Multi-year statin trials move IMT by hundredths of a millimetre. An uncontrolled 0.3 mm shift in half a year is far more likely to reflect measurement variability than arterial remodeling.

• No outcome data. Zero cardiovascular events, zero mortality, longest trial 6 months.

• Product heterogeneity. Trials used BPF at 38 percent polyphenols, Bergavit at 150 mg flavonoids, and various combination formulas. These are not interchangeable, and pooled analyses treat them as if they were.

• The phototoxicity evidence, by contrast, is old and solid. Zaynoun 1977, Dubertret 1990, Young 1990, Kaddu 2001, Weisenseel 2005, Driscoll 2021. It is the best-established fact about bergamot and the one least likely to appear on a bottle.

Summary & Key Takeaways

Bergamot is two products with one name, and the regulatory treatment of each is close to inverted. The peel oil carries a compound the fragrance industry restricts to 0.40 percent of a leave-on product and caps at 15 ppm of 5-MOP on sun-exposed skin, that the EU lists in the prohibited annex of its cosmetics regulation, and that IARC has classified as probably carcinogenic to humans since 1987. That same oil is sold undiluted in 10 mL bottles with no bergapten figure and no required warning. The juice extract, which carries the interesting chemistry and the actual clinical data, is sold with label language loose enough that two of the products sampled here name the wrong chemical class and one misspells the fruit.

Bottom Line

If you want the cholesterol effect, buy a named standardized extract that declares milligrams of flavanones, expect something in the range of 10 to 15 percent LDL-C reduction rather than the 40 percent the older uncontrolled trials advertise, give it 12 weeks, and check a lipid panel. If you want the smell on your skin in daylight, buy the bergapten-free or steam-distilled grade and ask the seller for the residual furocoumarin number in ppm. If they cannot supply it, they do not know what they are selling.

Key Safety Points

• Cold-pressed bergamot oil plus UVA causes real chemical burns. Keep it off skin that will see sun or a tanning bed for at least 12 to 24 hours, and remember that the 2001 case series includes a patient who was only exposed to the vapor.

• Sunscreen at ordinary in-product concentrations does not neutralize it.

• Bergamottin makes oral bergamot a plausible CYP3A4 problem. Simvastatin, lovastatin, tacrolimus, ciclosporin, apixaban and calcium channel blockers all warrant a conversation before starting.

• Do not substitute bergamot for statin therapy in anyone with established cardiovascular disease. There is no outcome trial, no mortality data and no trial longer than 6 months.

• Avoid oral extract in pregnancy and lactation, and avoid topical cold-pressed oil in children.

Special Note

There is a pattern here worth carrying to other shelves. When one industry regulates a compound to parts per million and another sells the same compound undiluted, the difference is almost never in the chemistry. It is in who is liable. The fragrance houses put bergamot oil in products used by hundreds of millions of people and had to answer for the burns, so they measured the bergapten and set a number. The aromatherapy trade sells small volumes to individuals who blame themselves for a sunburn, so nobody measured anything. Ask which industry has been sued over an ingredient, and you will usually find the industry that knows what is actually in it.